Evidence map›Paper›PMID 38727775›Full record

ArticleMolecular biology reports2024

Hepatoprotective effects of baicalein against liver ischemia-reperfusion injury and partial hepatectomy in a rat model.

Tetsuya Okuyama, Richi Nakatake, Kentaro Ito, Morihiko Ishizaki, Hidesuke Yanagida, Hiroaki Kitade, Katsuhiko Yoshizawa, Yukinobu Ikeya, Mikio Nishizawa, Mitsugu Sekimoto

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tetsuya Okuyama *Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan.
Richi Nakatake *Department of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan. nakatakr@hirakata.kmu.ac.jp.
Kentaro ItoDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, 525-8577, Shiga, Japan.
Morihiko IshizakiDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan.
Hidesuke YanagidaDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan.
Hiroaki KitadeDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan.
Katsuhiko YoshizawaDepartment of Innovative Food Sciences, School of Food Sciences and Nutrition, Mukogawa Women's University, 6-46 Ikebiraki-cho, Nishinomiya, 663-8558, Hyogo, Japan.
Yukinobu IkeyaFaculty of Pharmacy, Daiichi University of Pharmacy, 22-1 Tamagawa-machi, Minami-ku, Fukuoka, 815-8511, Fukuoka, Japan.
Mikio NishizawaDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, 525-8577, Shiga, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, 573-1010, Osaka, Japan.

Funding

Japan Society for the Promotion of Science 19K18370Japan Society for the Promotion of Science 21K08697
6 · The paper itself

Abstract

backgroundBaicalein is the main active flavonoid in Scutellariae Radix and is included in shosaikoto, a Kampo formula used for treating hepatitis and jaundice. However, little is known about its hepatoprotective effects against hepatic ischemia-reperfusion injury (HIRI), a severe clinical condition directly caused by interventional procedures. We aimed to investigate the hepatoprotective effects of baicalein against HIRI and partial hepatectomy (HIRI + PH) and its potential underlying mechanisms. METHODS AND

resultsMale Sprague-Dawley rats received either baicalein (5 mg/kg) or saline intraperitoneally and underwent a 70% hepatectomy 15 min after hepatic ischemia. After reperfusion, liver and blood samples were collected. Survival was monitored 30 min after hepatic ischemia and hepatectomy. In interleukin 1β (IL-1β)-treated primary cultured rat hepatocytes, the influence of baicalein on inflammatory mediator production and the associated signaling pathway was analyzed. Baicalein suppressed apoptosis and neutrophil infiltration, which are the features of HIRI + PH treatment-induced histological injury. Baicalein also reduced the mRNA expression of the proinflammatory cytokine tumor necrosis factor-α (TNF-α). In addition, HIRI + PH treatment induced liver enzyme deviations in the serum and hypertrophy of the remnant liver, which were suppressed by baicalein. In the lethal HIRI + PH treatment group, baicalein significantly reduced mortality. In IL-1β-treated rat hepatocytes, baicalein suppressed TNF-α and chemokine mRNA expression as well as the activation of nuclear factor-kappa B (NF-κB) and Akt.

conclusionsBaicalein treatment attenuates HIRI + PH-induced liver injury and may promote survival. This potential hepatoprotection may be partly related to suppressing inflammatory gene induction through the inhibition of NF-κB activity and Akt signaling in hepatocytes.

Indexed as

ApoptosisDisease Models, AnimalFlavanonesHepatectomyHepatocytesInterleukin-1betaLiverRats, Sprague-DawleyReperfusion InjuryAnimalsMaleNF-kappa BProtective AgentsProto-Oncogene Proteins c-aktRatsSignal TransductionbaicaleinFlavanonesInterleukin-1betaNF-kappa BProtective AgentsProto-Oncogene Proteins c-aktTumor Necrosis Factor-alphaBaicaleinHepatectomyHepatic ischemia-reperfusion injuryPrimary cultured hepatocytes

Identifiers

PMID38727775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.